Insmed Inc (INSM)

[Stockexpertpro]

Their ONLY Drug FAILED The company said just 2 months ago

http://www.cnbc.com/id/101526282

I dunno if you can even trust this company they only have 1 Drug that is in Phase 2 This Drug is for a VERY Rare Disease 700 Million Dollar market cap for a Bio Tech With ONLY 1 Drug NO Revenues Losing Millions Book Value around 3.60$ a share trading at 17.50$ looks not only over priced and way over valued with only 1 Drug in the pipeline anything goes wrong and apprently they have had ALOT of Problems with this drug and currently their is NO Cure Company also states in its SEC Filings it could take YEARS for it to Develop any drug

http://www.cnbc.comInsmed's lung infection drug fails mid-stage study, shares fall
Wednesday, 26 Mar 2014 | 7:47 AM ET
Reuters






COMMENTSStart the Discussion
(Adds details, background; updates share movement)

March 26 (Reuters) - Insmed Inc said its only experimental drug failed to meet the main goal of a mid-stage trial on patients with a form of bacterial lung infection, sending shares down 34 percent in premarket trade.

The company said the inhaled antibiotic Arikayce did not reduce bacterial density, a measure of change in infection, significantly enough in patients with treatment-resistant nontuberculous mycobacterial(NTM) lung infections.

Insmed compared the drug, in combination with a standard treatment, with a combination of placebo and the standard treatment.

This is the second setback for the company which said in July last year that Arikayce, formerly known as Arikace, did not show better results than a competing drug made by Novartis AG in a late-stage study.

Insmed said on Wednesday patients treated with Arikayce experienced a greater number of adverse events, including throat irritation, than those on placebo.

The company, however, said the adverse events were consistent with those seen in patients receiving inhaled antibiotics.

NTM lung infections are caused by a type of bacteria found in soil as well as water. An infection can cause severe lung disease characterized by cough, fever and blood in the mucus.

Insmed's shares, which were halted prior to the announcement, fell to $12.00 in premarket trade. They closed at $18.30 on the Nasdaq on Tuesday.

/id/101526282